Clinical trials: Cancer in the Lung, open to volunteers
Lung Carcinoma, Lung Non-Small Cell Carcinoma
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors…
- Conditions
- Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
- Trial name
- NCT05802186
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University
Non-Small Cell Lung Cancer
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with…
- Trial name
- NCT07824882
- Testing
- HS-20093 for Injection, Adebrelimab Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hansoh BioMedical R&D Company
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide…
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
- Trial name
- NCT05484583
- Testing
- Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab
- Volunteers
- 58 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Relapsed or Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the…
- Trial name
- NCT05503888
- Testing
- Almonertinib combined with SHR-1701, Almonertinib
- Volunteers
- 160 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lung Cancer (Diagnosis)
Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.
This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery.
- Trial name
- NCT07393490
- Testing
- Apnoeic Oxygenation, Standard Ventilation
- Where
- Croatia
- Volunteers
- 56 people
- Sponsor
- Osijek University Hospital
Advanced Squamous Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy…
- Trial name
- NCT07241039
- Testing
- ABBV-711, Budigalimab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- AbbVie
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Solid Tumor, Adult, Metastatic Solid Tumor
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab…
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
- Trial name
- NCT05856981
- Testing
- ADU-1805, Pembrolizumab
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 130 people
- Sponsor
- Sairopa B.V.
Non Small Cell Lung Cancer NSCLC
A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called "syndromes") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer.
- Trial name
- NCT07338396
- Testing
- EGFR-TKI
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Non-Small Cell Lung Cancer
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally…
- Trial name
- WUKONG-32 (NCT06348927)
- Testing
- sunvozertinib in combination with Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Hunan Province Tumor Hospital
SCLC, Extensive Stage
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
This is a phase I study to evaluate the safety and preliminary efficacy of [225Ac]Ac-DOTATATE injection combined with tislelizumab in the maintenance treatment period for patients of extensive-stage small cell lung cancer…
- Trial name
- NCT07413042
- Testing
- [225Ac]Ac-DOTATATE
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
Non-small Cell Lung Carcinoma
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This is a three-stage study, consisting of Phase Ia dose-escalation, Phase Ib dose expansion, and a Phase II component.
- Trial name
- NCT05393466
- Testing
- BPI-361175
- Volunteers
- 30 people
- Sponsor
- Xcovery Holdings, Inc.
Progression
A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
- Trial name
- NCT04905056
- Testing
- Ablation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Adenocarcinoma, Cholangiocarcinoma
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic…
- Conditions
- Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer
- Trial name
- NCT06199895
- Testing
- Paclitaxel Polymeric Micelles for Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Liu Huang
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal…
- Trial name
- AmiNA (NCT07586202)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
- Trial name
- NCT04996121
- Testing
- XZP-5955 tablets
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Lung Cancer (NSCLC)
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-naïve, advanced ROS1-positive non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07083687
- Testing
- Lorlatinib 100 mg
- Volunteers
- 21 people
- Sponsor
- Hunan Cancer Hospital
Large Cell Neuroendocrine Carcinoma of the Lung
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced…
- Trial name
- FIRST-NEC (NCT06393816)
- Testing
- Durvalumab with etoposide and Carboplatin/Cisplatin
- Where
- 31 sites in France, Reunion
- Volunteers
- 80 people
- Sponsor
- Centre Leon Berard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.